These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 15062175)

  • 1. What is the optimal dose for 125I prostate implants? A dose-response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptoms.
    Stock RG; Stone NN; Dahlal M; Lo YC
    Brachytherapy; 2002; 1(2):83-9. PubMed ID: 15062175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dose-response study for I-125 prostate implants.
    Stock RG; Stone NN; Tabert A; Iannuzzi C; DeWyngaert JK
    Int J Radiat Oncol Biol Phys; 1998 Apr; 41(1):101-8. PubMed ID: 9588923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
    Kollmeier MA; Stock RG; Stone N
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isotope selection for patients undergoing prostate brachytherapy.
    Cha CM; Potters L; Ashley R; Freeman K; Wang XH; Waldbaum R; Leibel S
    Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):391-5. PubMed ID: 10487561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of prostate volume on dosimetry results in real-time 125I seed implantation.
    McNeely LK; Stone NN; Presser J; Chircus JH; Stock RG
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):292-9. PubMed ID: 14697451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.
    Ho AY; Burri RJ; Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):16-22. PubMed ID: 19289266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (125)I monotherapy using D90 implant doses of 180 Gy or greater.
    Kao J; Stone NN; Lavaf A; Dumane V; Cesaretti JA; Stock RG
    Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):96-101. PubMed ID: 17980505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy.
    Stone NN; Stock RG
    Brachytherapy; 2003; 2(1):32-9. PubMed ID: 15062161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary symptom flare following I-125 prostate brachytherapy.
    Cesaretti JA; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):1085-92. PubMed ID: 12829146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dosimetry doesn't seem to predict the control of organ-confined prostate cancer after I-125 brachytherapy. Evaluation in 150 patients.
    Gastaldi E; Chiono L; Gallo F; Schenone M; Ninotta G; Chiarlone R; Ghiso G; Giberti C
    Arch Ital Urol Androl; 2009 Dec; 81(4):215-7. PubMed ID: 20608144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation.
    Gelblum DY; Potters L; Ashley R; Waldbaum R; Wang XH; Leibel S
    Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):59-67. PubMed ID: 10477007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathologic evidence of dose-response and dose-volume relationships for prostate cancer treated with combined external beam radiotherapy and high-dose-rate brachytherapy.
    Kestin LL; Goldstein NS; Vicini FA; Mitchell C; Gustafson GS; Stromberg JS; Chen PY; Martinez AA
    Int J Radiat Oncol Biol Phys; 2002 Sep; 54(1):107-18. PubMed ID: 12182980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute urinary morbidity following I-125 interstitial implantation of the prostate gland.
    Desai J; Stock RG; Stone NN; Iannuzzi C; DeWyngaert JK
    Radiat Oncol Investig; 1998; 6(3):135-41. PubMed ID: 9652912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy.
    Potters L; Cao Y; Calugaru E; Torre T; Fearn P; Wang XH
    Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):605-14. PubMed ID: 11395226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.
    Stock RG; Stone NN
    Brachytherapy; 2002; 1(1):2-10. PubMed ID: 15062181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermediate term biochemical-free progression and local control following 125iodine brachytherapy for prostate cancer.
    Stone NN; Stock RG; Unger P
    J Urol; 2005 Mar; 173(3):803-7. PubMed ID: 15711273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of disease and treatment-related factors on biopsy results after prostate brachytherapy: implications for treatment optimization.
    Stock RG; Stone NN; Kao J; Iannuzzi C; Unger P
    Cancer; 2000 Oct; 89(8):1829-34. PubMed ID: 11042580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-up.
    Keyes M; Miller S; Moravan V; Pickles T; Liu M; Spadinger I; Lapointe V; Morris WJ
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):649-55. PubMed ID: 19211199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late urinary side effects 10 years after low-dose-rate prostate brachytherapy: population-based results from a multiphysician practice treating with a standardized protocol and uniform dosimetric goals.
    Keyes M; Miller S; Pickles T; Halperin R; Kwan W; Lapointe V; McKenzie M; Spadinger I; Pai H; Chan EK; Morris WJ
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):570-8. PubMed ID: 25151536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.